A Phase 1/2 Trial of CBL0137 (NSC# 825802) in Patients With Relapsed or Refractory Solid Tumors Including CNS Tumors and Lymphoma
This study is testing an experimental drug called CBL0137 to see how well it works against solid tumors, lymphoma, and brain cancers that have returned or stopped responding to standard treatments. By blocking specific signals inside cancer cells, researchers hope to stop them from growing or help them die off.
This trial is for patients with various solid tumors or lymphoma who have already tried standard treatments without success. You must be physically active enough to handle daily tasks and have recovered from the immediate side effects of your previous cancer treatments.
Participants will receive the study drug and undergo regular health checks, including blood tests, heart ultrasounds, and sometimes small tissue or bone marrow samples. The goal is to find the right dose and see how your body reacts to the treatment.
The study is currently recruiting patients at medical centers in Birmingham, Alabama; Phoenix, Arizona; and Los Angeles, California. Please talk to your oncologist to see if this is an option for your specific situation.
- 1The study focuses on cancers that have not responded to or have returned after standard treatment.
- 2Participants will receive an experimental drug designed to interfere with how cancer cells survive.
- 3Frequent check-ups and medical tests are required to monitor your safety and the effectiveness of the drug.
No related links yet
Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.
Suggest a linkThis summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.